BACKGROUND: Heparin-induced thrombocytopenia type II (HIT II) correlates with a higher incidence of thromboembolic complications and unfavorable outcome. OBJECTIVE: To examine the risk factors and outcomes for patients with HIT II with aneurysmal subarachnoid hemorrhage. METHODS: Demographics, risk factors, treatments, and outcomes data of 600 aneurysmal subarachnoid hemorrhage patients admitted to the University of Illinois Medical Center in Chicago between June 2002 and July 2007 were retrospectively reviewed. Patients meeting the clinical criteria for HIT II were compared with those who did not develop thrombocytopenia. RESULTS: Twenty-five patients (6%) met the clinical criteria for HIT II, and 396 (94%) did not develop thrombocytopenia. Both groups were the same with respect to age, HuntHess score and Fisher grade on admission, medical conditions, and social risk factors. The HIT II patients had significantly more unfavorable outcomes (modified Rankin Scale score .3), deep vein thrombosis, stroke, pulmonary embolism, and death. Development of HIT II was strongly associated with symptomatic vasospasm (odds ratio, 5.7; 95% confidence interval, 2.5-13.1; P , .001) and number of angiographic procedures (odds ratio, 1.7; 95% confidence interval, 1.3-2.2; P , .001). Forward buildup selection modeling demonstrated the latter to be the strongest predictor for HIT II development (odds ratio, 2.3; 95% confidence interval, 1.7-3.2; P = .02). CONCLUSION: Heparin-induced thrombocytopenia type II correlates with a worse outcome and higher risk of thromboembolic complications in aneurysmal subarachnoid hemorrhage patients. In addition, HIT II was strongly associated with the number of angiographic procedures performed during the same hospitalization.
H eparin-induced thrombocytopenia type II (HIT II) affects 0.2% to 3% of all patients treated with heparin anticoagulation therapy. [1] [2] [3] The rate of thrombotic complications associated with HIT II is approximately 23% to 52% and is associated with thrombotic death rates of 4% to 5%. 4 The most common complications are thromboses of the large vessels, with subsequent gangrene and limb amputation, stroke, myocardial infarction, deep vein thrombosis (DVT), pulmonary embolism, thrombosis of the cerebral venous sinuses, disseminated intravascular coagulation, and adrenal necrosis. 5 Heparin is used routinely as an anticoagulant for DVT prophylaxis in neurosurgical patients, and its therapeutic use is increasing with the growing prevalence of endovascular procedures. The reported incidences of HIT II in patients with subarachnoid hemorrhage (SAH) and aneurysmal SAH (aSAH) reported in 2 studies were 15% 6 and 5.3%, 7 respectively. In both studies, HIT II patients had significantly higher rates of thrombotic complications and less favorable outcomes; however, the risk factors for the incidence of HIT II in aSAH patients have not been described. In this study, we focused on the risk factors and predictors for development of HIT II in aSAH patients at our institution.
METHODS Patient Population
The medical records of 600 consecutive patients admitted to the neurosurgical intensive care unit with aSAH at the University of Illinois Medical Center at Chicago between June 2002 and July 2007 were retrospectively reviewed. The study was approved by the Institutional Review Board at the University of Illinois at Chicago. Admission computed tomography (CT) scans or lumbar puncture if the CT was nondiagnostic was used to diagnose SAH. Intracranial cerebral aneurysm was confirmed by 4-vessel cerebral angiography in all patients. Patient demographic, clinical, and radiographic data were retrospectively collected. All patients were evaluated for any drop in platelet count during their hospitalization.
Clinical Management
All patients were managed in a neurosurgical intensive care unit. Patients with evidence of acute hydrocephalus received an external ventricular drain. All patients received peripheral arterial and central venous lines, which were maintained with heparinized saline flushes. Diagnostic angiography and aneurysm repair were performed within 24 hours of admission when possible. Aneurysms were treated with coiling if the anatomy was favorable; otherwise, they were surgically secured with clipping. As per our standard institutional protocol, patients postoperatively received 5000 IU unfractionated heparin (UFH) subcutaneously 2 or 3 times daily for DVT prophylaxis, depending on patient's weight, age, and partial thromboplastin time level during the period of administration. During cerebral angiography, the sheath and catheter were constantly flushed with heparinized saline 2000 U/L 0.9% normal saline. Patients who underwent interventional treatments (aneurysm coiling, angioplasty, or intra-arterial infusion of vasodilators for vasospasm) were given intravenous heparin to maintain activated clotting time . 200 seconds during the procedure. Angiographic vasospasm was diagnosed by 4-vessel cerebral angiography interpreted by a neurointerventionalist. Transcranial Doppler ultrasonography was also performed daily for vasospasm screening. Clinical vasospasm was defined as any change in neurological examination in the presence of angiographic vasospasm not attributable to other causes. Short-term outcome was assessed with the modified Rankin Scale at the time of discharge from the intensive care unit.
Diagnostic Criteria for HIT II
Heparin-induced thrombocytopenia type II was diagnosed in accordance with the American College of Chest Physicians (ACCP) conference and previously described clinical criteria as used by prior studies [6] [7] [8] [9] [10] [11] [12] defined as thrombocytopenia occurring 4 to 14 days after the beginning of heparin therapy, platelet reduction to , 150 000 per 1 mL or , 50% of baseline, exclusion of other causes of thrombocytopenia, and recovery of platelet levels after heparin cessation. Heparin/PF4-platelet antibody enzyme-linked immunosorbent assay was performed on patients with clinical HIT II; however, the results were not considered necessary for diagnosis.
Statistical Analysis
The primary analysis consisted of comparison between 2 groups: clinical HIT II-positive patients and patients without a drop in platelet count , 150 000 per 1 mL or 50% of baseline (the control group). Patients who developed thrombocytopenia, ie, a platelet count ,150 000 per 1 mL and/or , 50% of baseline, but could not be documented to meet all of the clinical criteria for HIT II were excluded from the primary analysis; this cohort consisted of patients with early thrombocytopenia (within 4 days), a single abnormal laboratory value not confirmed on repeat testing, and recovery of platelet counts despite apparent continuation of heparin. Although this cohort was likely overwhelmingly HIT negative, it was felt that the group may include some HIT-positive patients who were not appropriately identified owing to lack of adequate documentation. A secondary analysis was subsequently performed including this cohort of thrombocytopenic patients within the control group to ensure that exclusion of thrombocytopenic patients did not create a significant bias in terms of outcomes. Categorical data were compared by use of x 2 tests, and continuous data were compared by use of unpaired Student t tests. We compared the risk of developing HIT II on the basis of demographics, medical history, and treatments. A value of P , .05 was considered significant for all analyses; all tests were 2 sided. The risk factors between the HIT II-positive and HIT II-negative groups were compared by use of univariate analysis with regression methods. For statistically positive parameters (P , .05) between the 2 groups, multivariate analysis was performed. For interdependent positive risk factors, forward selection model buildup 13 was performed to determine which factor was more predictive of HIT II development. Despite the potential limitations of this model, whereby addition of new variables may render prior variables nonsignificant, this was thought to be the most appropriate analysis in the setting of potentially interdependent variables. The relationship between the number of angiogram procedures (including interventional treatments) and the development of HIT II was evaluated with the Cochran-Armitage trend test. 14, 15 Statistical analyses were performed with commercially available Statistical Data Software STATA10 (StataCorp, College Station, Texas) and SAS (SAS Institute Inc, Cary, North Carolina).
RESULTS

Patient Cohort Characteristics
Of 600 patients with aSAH, 179 patients with thrombocytopenia but not meeting HIT clinical criteria were excluded from the primary analysis. In total, 421 patients with aSAH were included in the primary analysis ( Table 1 ). The mean age of the patient cohort was 53.2 6 13.1 years (mean 6 SD). Two hundred eighty-five patients (68%) were female. Three hundred nine patients (73%) presented with good neurological grade (Hunt and Hess scores I-III), and 98 patients (23%) presented with Fisher grade 1 to 2. Two hundred sixty-eight patients (64%) had anterior circulation aneurysms. One hundred ninety-seven patients (47%) were treated surgically; 203 patients (48%) were treated endovascularly; and 21 patients were untreated (brain death or care withdrawn). Three hundred sixteen patients (75%) required external ventricular drain placement for acute hydrocephalus. Twenty-eight patients (7%) presented with vasospasm on the initial angiogram.
Incidence of HIT II
Of the 421 aSAH patients, 25 (6%) met the clinical diagnostic criteria for HIT II. The mean platelet count nadir of these HIT II patients was 99 6 37 per 1 mL (mean 6 SD). On average, HIT II developed on day 9.8 after admission to the hospital (range, 4-21 days). Twenty-three HIT II patients underwent a heparin/ PF4-platelet antibody enzyme-linked immunosorbent assay test, all of which were positive. Table 1 lists the demographic and clinical characteristics of the aSAH patients with HIT II and the control group. Both groups were comparable in terms of age, sex, race, Hunt-Hess score, Fisher grade, vasospasm on presentation, statin intake, smoking, cocaine use, renal disease, cardiac disease, hypertension, non-insulin-dependent diabetes mellitus, and hypercholesterolemia. Compared with control patients, HIT II patients had more often undergone aneurysm clipping (76% vs 45%; P , .01) and more commonly required external ventricular drain placement (96% vs 74%; P , .01). Heparininduced thrombocytopenia type II was strongly associated with symptomatic vasospasm (odds ratio [OR], 5.7; 95% confidence interval [CI], 2.5-13.5; P , .001), angiographic vasospasm severity (OR, 2.2; 95% CI, 1.1-4.2; P = .02), and higher maximum transcranial Doppler values (166.6 6 56.4 vs 141.6 6 51.6; P = .02). Patients affected by HIT II required more angioplasty procedures, including intra-arterial infusion of vasodilators for vasospasm (OR, 1.9; 95% CI, 1.4-2.4; P , .001). 28 (7) 3 (17) 12 (10) NS (.44) Statin intake (PTA), n (%)
48 (12) 5 (21) 43 (11) NS (.09) Smoking, n (%)
202 (51) 9 (39) 193 (51) NS (.10) Cocaine use, n (%) 29 (7) 1 (4) 28 (7) NS (.31) Renal disease, n (%) 20 (5) 2 (8) 18 (5) NS (.23) Cardiac disease, n (%)
17 (4) 3 (12) 14 (4) NS (.06) Hypertension, n (%)
190 (46) 13 (52) 177 (45) NS (.13) Non-insulin-dependent diabetes mellitus, n (%)
26 (6) 1 (4) 25 (6) 
Risk Factors for HIT II
Because symptomatic vasospasm and interventional procedures were strongly associated with the diagnosis of HIT II, only symptomatic vasospasm and interventional procedures occurring before the diagnosis of HIT II were considered in the risk factor analysis. Univariate analysis revealed positive correlations between the incidence of HIT II and both angiographic vasospasm severity (OR, 2.32; 95% CI, 1.3-4.4; P = .02) and the incidence of symptomatic vasospasm (OR, 5.7; 95% CI, 2.5-13.55; P , .001). Incidence of HIT II also correlated with the number of angiogram procedures (OR, 1.7; 95% CI, 1.3-2.2; P , .001) and interventional treatments (OR, 1.5; 95% CI, 1.1-2.1; P = .01) performed before the diagnosis of HIT II (Table 2) . On multivariate analysis, both symptomatic vasospasm (OR, 3.6; 95% CI, 1.24-10.80; P , .5) and number of angiogram procedures (OR, 1.54; 95% CI, 1.14-2.08; P , .01) remained positive predictors for HIT II. Because patients with vasospasm require additional angiography procedures for evaluation and treatment, these factors are interdependent. Therefore, forward selection model buildup was performed to demonstrate the most significant predictor for HIT II, which indicated that the total number of angiogram procedures (including interventional treatments) before the diagnosis of HIT II was the more important risk factor (OR, 2.30; 95% CI, 1.7-3.2; P = .02; pseudo R 2 = 0.68; Table 2 ). The Cochran-Armitage trend test demonstrated a positive correlation between the prevalence of clinical HIT II-positive patients and the number of angiogram procedures (including interventional treatments; P , .001; Figure) . Table 3 summarizes the clinical outcomes of each group. Patients with HIT II exhibited a higher incidence of systemic thrombotic complications, including lower-extremity DVT, stroke, and pulmonary embolism. For the neurological outcome and death outcome, 24 patients who received no treatment for their aneurysms and/or had withdrawal of care were excluded from this analysis. Unfavorable neurological outcome, defined as modified Rankin Scale . 3, was more common in HIT II patients on univariate (P = .001) and multivariate (P = .05) analyses. Four patients (16%) with HIT II died compared with 18 patients (4.7%) in the control group (P = .013, multivariate analysis). Patients with HIT II tend to stay in the intensive care unit for a longer period of time (average intensive care unit stay, 27.4 vs 18.9 days; P , .05).
Clinical Outcome
Results were found to be very similar on secondary analysis when the HIT II patients were compared with the full cohort of non-HIT patients (those with and without thrombocytopenia; Table 4 ) and even when the HIT II patients were compared with only the thrombocytopenic cohort in terms of stroke and lower-extremity DVT, with a trend for unfavorable outcome, death, and pulmonary embolism (data not shown).
Heparin treatment was discontinued for all patients affected by HIT II; however, antithrombin therapy was initiated in only 16 patients (64%) and was withheld in the remainder because of the risk for postoperative hemorrhage, lack of evidence of thrombosis, and/or increasing platelet counts immediately after cessation of heparin.
For prolonged anticoagulation, 3 patients (12%) received warfarin, 4 patients (16%) received argatroban, 4 patients (16%) received lepirudin, and 5 patients (20%) received fondaparinux.
DISCUSSION
Heparin-induced thrombocytopenia type II is caused by a type II hypersensitivity reaction against heparin/PF4 complexes that results in marked thrombocytopenia and systemic thrombotic complications. 16 PF4 is a chemokine released from a granules during platelet activation. 17 Heparin-induced thrombocytopenia type II typically occurs 4 to 14 days after the initiation of heparin therapy but may occur sooner in previously sensitized patients. 10 The definition of HIT II used in this study was based on criteria cited by the ACCP conference 3,9,12 and those used in previous studies of HIT II patients. 3, 6, 7, 12 We used the heparin/PF4 enzyme-linked immunosorbent assay titer only to confirm clinically diagnosed HIT II, as recommended by the Eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. 9, 18 Heparin-induced thrombocytopenia type II is scarcely reported in the neurosurgical literature. Rogers 19 described a case of HIT II after heparin flushing during a carotid endarterectomy. The patient developed 2 postsurgical hematomas. The patient's platelet count decreased to 93 000 per 1 mL. Parney and Steinke 20 also described a patient with aSAH who developed HIT II after heparin flushing of indwelling catheters. The patient suffered a hemorrhagic stroke with a platelet count of 52 000 per 1 mL. In a retrospective study of 389 SAH patients over a 3.5-year period, Hoh et al 6 found a 15% incidence of clinical HIT II. These findings were attributed to heparin exposure during endovascular procedures and from heparinized indwelling catheters. Kim et al 7 retrospectively compared the incidence of HIT II in 166 aSAH patients treated with UFH and 134 patients treated with low-molecular-weight heparin (LMWH) over a 4-year period. Although LMWH has been considered to pose a lower risk for the development of HIT, 21 the overall incidence of HIT II was 5.3% and was not significantly different between the 2 treatment groups. The authors offer in this study 2 explanations for the much lower incidence of HIT II observed in their cohort. First, unlike the previous study, the patients' vascular catheters were not maintained with heparinized saline. Second, a larger proportion of HIT II patients in the study by Hoh et al heparin, which in turn increased the incidence of HIT II. The incidence of HIT II observed in our cohort of aSAH patients was consistent with those reported by Kim et al 7 (5.3%). The multivariate analysis identified the following predictors of HIT II occurrence: presence of symptomatic vasospasm before HIT II diagnosis and total number of angiograms (including interventional treatments) before HIT II diagnosis. Because those factors are interdependent (ie, vasospasm severity and the number of interventional treatments), a forward selection model analysis was performed to determine the strongest correlation. This demonstrated that the total number of angiogram procedures, including interventional treatments (coiling, angioplasty, or intraarterial infusion of vasodilators), is the strongest predictor for the occurrence of HIT II (OR, 2.3; 95% CI, 1.7-3.2; P = .02). As the number of angiogram procedures (including interventional treatments) increases, the risk for developing HIT II increases (Figure) with a positive Cochran-Armitage trend test (P , .001).
This is the first report to indicate that a higher number of angiogram procedures during a short period of hospitalization increases the risk of HIT II. Our findings may account for the results of Kim et al, 7 who showed that in aSAH patients the incidence of HIT II is not dependent on whether UFH or LMWH is used for DVT prophylaxis. In our cohort, the predominant risk factor for HIT II was the number of angiographic procedures, which would outweigh any difference in risk associated with UFH vs LMWH. Whether the major contributory factor associated with angiographic procedures is the cumulative amount of heparin exposure, endothelial injury with resultant platelet activation and increased release of PF4, or a combination of both is unknown. These patients are exposed to higher levels of heparin in the form of heparinized saline flushing (2000 IU/L), indwelling arterial catheters, and intravenous boluses used to maintain therapeutic activated clotting time during interventional procedures. Documentation of the amount of heparin given during the procedure was not available to evaluate whether there was a cumulative dose effect from heparin exposure. Prior reports show that even small doses of UFH and LMWH administered by any route, including heparin coatings on vascular catheters, may trigger HIT II. 1, 19, 22 However, no studies have addressed the relative risk of different routes of exposure using the same heparin preparation or quantified the risk associated with cumulative heparin exposure. Our study suggests that a higher incidence of HIT II may be due to dose, route of exposure, or associated endothelial injury or might be a cumulative effect of prior exposure.
We found a significantly higher incidence of systemic thrombotic complications in patients with HIT II, including lowerextremity DVT (40% vs 13%; P , .01), stroke (52% vs 14%; P , .001), and pulmonary embolism (16% vs 5%; P = .03). On multivariate analysis, these patients also had significantly worse outcomes at the time of discharge from the intensive care unit (72% vs 33%; P , .01) compared with the control group without thrombocytopenia. Results were found to be very similar on secondary analysis when the HIT II patients were compared with the full cohort of non-HIT patients (those with and without thrombocytopenia; Table 4 ).
In addition, the mortality rate in patients who received treatment for their aneurysms appears to be higher in the HIT II group (16% vs 4.7%; P = .02). These findings are consistent with those reported by Hoh et al 6 and Kim et al. 7 In addition to the discontinuation of all heparin treatments, contemporary standards for the management of HIT II include immediate institution of alternative anticoagulation. 23 Direct thrombin inhibitors (eg, lepirudin, argatroban, and bivalirudin) and pentasaccharides (eg, fondaparinux) are all acceptable. 24 Warfarin is contraindicated as an immediate alternative agent because the associated early transient hypercoagulable state may cause venous gangrene. 24 Although heparin treatment was discontinued for all patients in our series affected by HIT II, antithrombin therapy was initiated in only 16 patients (52%) owing to perceived risk or postoperative hemorrhage, recovery, platelet counts, and/or lack of evidence for thrombosis. Three of our HIT II patients received warfarin for prolonged anticoagulation.
This study has several potential limitations. Specifically, retrospective determination of outcomes and end points may lead to ascertainment bias. The retrospective nature of the study also resulted in incomplete availability of data for all parameters of interest. Information such as the cumulative dose of heparin exposure could not be gleaned from the medical charts retrospectively, although it would have been of significant interest to analyze its effect on the risk of developing HIT II. Incomplete data also contributed to reduced certainty regarding the thrombocytopenic patients who did not meet clinical HIT criteria and to their exclusion from primary analysis. Given that thrombocytopenia alone can be a marker for critical illness, 12 the exclusion of these patients might create a larger difference between the HIT II and control group in terms of outcomes. Consequently, secondary analysis was performed with the inclusion of the thrombocytopenic patients in the control group, which did not substantively affect the overall results.
CONCLUSION
Heparin-induced thrombocytopenia type II is associated with a worse outcome and higher risk of thromboembolic complications in aSAH patients. Development of HIT II was most strongly associated with the number of interventional procedures performed.
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